Onkologiezentrum Donauwörth
- Address
- Neudegger Allee 10, Bayern, 86609 Donauwörth, Germany
Neoplasms (Breast Cancer)
The research at Onkologiezentrum Donauwörth focuses on advanced ER‑positive, HER2‑negative breast cancer, evaluating newer endocrine strategies to improve progression‑free survival. Trials compare a selective estrogen receptor degrader with standard endocrine options and explore the added benefit of a CDK4/6 inhibitor, especially in patients harboring ESR1 mutations.
- Optimization of endocrine therapy sequencing
- Impact of ESR1 mutations on treatment response
- Combination of selective estrogen receptor degraders and CDK4/6 inhibitors
- Progression‑free survival as primary efficacy endpoint
The site’s multidisciplinary team supports patient enrollment and monitors outcomes to advance personalized breast‑cancer care.
Hemic and Lymphatic Diseases (Chronic Lymphocytic Leukemia)
At Onkologiezentrum Donauwörth, investigators are studying high‑risk chronic lymphocytic leukemia defined by genetic abnormalities such as 17p deletion, TP53 mutation, complex karyotype, or unmutated IGHV. The goal is to assess whether a triple regimen of a BTK inhibitor, an anti‑CD20 antibody, and a BCL‑2 antagonist can extend progression‑free survival compared with a double‑therapy backbone.
- High‑risk genetic profiling for patient stratification
- Targeted BTK inhibition combined with anti‑CD20 therapy
- Integration of BCL‑2 inhibition to deepen responses
- Evaluation of progression‑free survival benefits
The center provides comprehensive care for CLL patients, facilitating access to innovative combination treatments.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1University Of Cologne1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Onkologiezentrum Donauwörth
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Randomized Open-label Study of Imlunestrant, Abemaciclib, and Endocrine Therapy in ER+ HER2- Advanced Breast Cancer Post-Endocrine Treatment | Eli Lilly & Co. | Phase III | Not Recruiting | Sep 2021 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abemaciclib | 1 | Unknown | 2021-09-30 | 2021-09-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.